Difference between revisions of "Pegaspargase (Oncaspar)"
| Line 1: | Line 1: | ||
| + | Also known as PEG-L-asparaginase, Peg-asparginase, Pegasparaginase. | ||
| + | |||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://oncaspar.com/pdf/OncasparPI.pdf | + | Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase. The Oncaspar formulation involves L-asparaginase (L-asparagine amidohydrolase) being covalently conjugated to monomethoxypolyethylene glycol, increasing its half-life and |
| − | <br>Route: | + | (mPEG) reducing the risk of hypersensitivity reactions in patients who have history of hypersensitivity to [[Asparaginase (Elspar)]].<ref name="insert">[http://oncaspar.com/pdf/OncasparPI.pdf Pegaspargase (Oncaspar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/pegaspargase.pdf Pegaspargase (Oncaspar) package insert (locally hosted backup)]</ref> |
| − | <br>Extravasation: | + | <br>Route: IV, IM |
| + | <br>Extravasation: no information | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/bio/peglasparaginase.asp | + | *[http://chemocare.com/bio/peglasparaginase.asp Pegaspargase (Oncaspar) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/peglasparaginase.asp Pegaspargase (Oncaspar) patient drug information (Chemocare)]</ref> |
| − | *[http://www.uptodate.com/contents/ | + | *[http://www.uptodate.com/contents/pegaspargase-patient-drug-information Pegaspargase (Oncaspar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pegaspargase-patient-drug-information Pegaspargase (Oncaspar) patient drug information (UpToDate)]</ref> |
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 16:43, 24 February 2012
Also known as PEG-L-asparaginase, Peg-asparginase, Pegasparaginase.
General information
Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase. The Oncaspar formulation involves L-asparaginase (L-asparagine amidohydrolase) being covalently conjugated to monomethoxypolyethylene glycol, increasing its half-life and
(mPEG) reducing the risk of hypersensitivity reactions in patients who have history of hypersensitivity to Asparaginase (Elspar).[1][2]
Route: IV, IM
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Pegaspargase (Oncaspar) patient drug information (Chemocare)[3]
- Pegaspargase (Oncaspar) patient drug information (UpToDate)[4]